Eli Lilly Shares Rise After Foundayo Shows More Weight Loss

Eli Lilly (LLY) edged 1% higher in morning Tuesday trading after new data pointed to greater weight and blood-sugar reductions from its oral Foundayo treatment than oral semaglutide at higher doses.The analysis examined 17.2 mg of Foundayo, or orforglipron, in adults with type 2 diabetes. At week 5…